Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR ARCUTIS' ZORYVE (ROFLUMILAST) CREAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AGES 2 TO 5

INVESTIGATIONAL ZORYVE CREAM 0.05% WAS FORMULATED FOR THE DELICATE SKIN OF INFANTS AND YOUNG CHILDREN WITH MILD TO MODERATE ATOPIC DERMATITIS TOPLINE RESULTS ANTICIPATED IN Q1 2026 THE U.S. FDA APPROVED ZORYVE CREAM 0.05% FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN CHILDREN AGES 2 TO 5 YEARS IN OCTOBER 2025 ATOPIC DERMATITIS IMPACTS 9.6 MILLION CHILDREN IN THE U.S., WITH UP TO 60% DEVELOPING SYMPTOMS WITHIN THEIR FIRST YEAR WESTLAKE VILLAGE, CALIF., NOV. 13, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE ENROLLMENT OF THE LAST SUBJECT IN THE INTEGUMENT-INFANT PHASE 2 OPEN-LABEL CLINICAL STUDY, WHICH IS EVALUATING THE SAFETY AND TOLERABILITY OF INVESTIGATIONAL ONCE-DAILY ZORYVE (ROFLUMILAST) CREAM 0.05% IN INFANTS AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS.

ARCUTIS COMPLETES ENROLLMENT IN INTEGUMENT-INFANT PHASE 2 STUDY EVALUATING ZORYVE (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH ATOPIC DERMATITIS

WESTLAKE VILLAGE, CALIF., NOV. 07, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 51,000 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK TO SIX NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF NOVEMBER 3, 2025, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

ARCUTIS ANNOUNCES PUBLICATION OF POSITIVE LONG-TERM SAFETY AND EFFICACY DATA OF ZORYVE (ROFLUMILAST) FOAM 0.3% IN INDIVIDUALS WITH SEBORRHEIC DERMATITIS

ARCUTIS ANNOUNCES PUBLICATION OF POSITIVE LONG-TERM SAFETY AND EFFICACY DATA OF ZORYVE (ROFLUMILAST) FOAM 0.3% IN INDIVIDUALS WITH SEBORRHEIC DERMATITIS IN AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

TORI SPELLING SHARES HER AND HER FAMILY'S JOURNEY WITH ECZEMA AND SEBORRHEIC DERMATITIS TO ENCOURAGE OTHERS TO TAKE CONTROL OF THEIR SKIN HEALTH ZORYVE (ROFLUMILAST) IS THE #1 PRESCRIBED BRANDED TOPICAL THERAPY FOR THREE MAJOR INFLAMMATORY SKIN CONDITIONS COMBINED  ECZEMA, PLAQUE PSORIASIS, AND SEBORRHEIC DERMATITIS WESTLAKE VILLAGE, CALIF., OCT. 30, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.(NASDAQ:ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE FREE TO BE ME AWARENESS CAMPAIGN FEATURING ACTRESS TORI SPELLING, AND HER DAUGHTER, STELLA (17).

MOTHER-DAUGHTER DUO, TORI SPELLING AND STELLA MCDERMOTT, PARTNER WITH ARCUTIS BIOTHERAPEUTICS IN THE FREE TO BE ME CAMPAIGN, URGING PEOPLE WITH INFLAMMATORY SKIN CONDITIONS TO SPEAK WITH THEIR HEALTHCARE PROVIDER ABOUT LONG-TERM TREATMENTS

ONCE-DAILY, EFFECTIVE, SAFE, AND WELL-TOLERATED ZORYVE CREAM 0.05% NOW COMMERCIALLY AVAILABLE FOR CHILDREN AS YOUNG AS AGE 2 ZORYVE CREAM 0.05% PROVIDES RAPID CLEARANCE OF ATOPIC DERMATITIS ZORYVE CAN BE USED ANYWHERE ON THE BODY FOR ANY DURATION AND IS NOT A STEROID ATOPIC DERMATITIS IS THE MOST COMMON TYPE OF ECZEMA, AFFECTING APPROXIMATELY 9.6 MILLION CHILDREN IN THE U.S. WESTLAKE VILLAGE, CALIF., OCT. 30, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE COMMERCIAL LAUNCH OF ZORYVE (ROFLUMILAST) CREAM 0.05% FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN CHILDREN AGES 2 TO 5 YEARS IN THE UNITED STATES.

ARCUTIS LAUNCHES ZORYVE (ROFLUMILAST) CREAM 0.05% FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN CHILDREN AGES 2 TO 5

Q3 2025 NET PRODUCT REVENUE FOR ZORYVE (ROFLUMILAST) WAS $99.2 MILLION, A 122% INCREASE COMPARED TO Q3 OF 2024, AND A 22% INCREASE COMPARED TO Q2 OF 2025 ZORYVE CREAM 0.05% RECEIVED U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR THE TREATMENT OF ATOPIC DERMATITIS IN CHILDREN DOWN TO 2 YEARS OF AGE IN OCTOBER COMPANY PROVIDES INITIAL 2026 FULL YEAR NET PRODUCT SALES GUIDANCE OF $455$470 MILLION WESTLAKE VILLAGE, CALIF., OCT. 28, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY OUTLINED ITS STRATEGY TO ACHIEVE SUSTAINABLE GROWTH AND REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER30, 2025.

ARCUTIS OUTLINES STRATEGY FOR DRIVING SUSTAINABLE GROWTH AND ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS

WESTLAKE VILLAGE, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.(NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT ARCUTIS MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES.

ARCUTIS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

WESTLAKE VILLAGE, CALIF. AND LAS VEGAS, OCT. 24, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT NEW DATA DEMONSTRATING ZORYVE (ROFLUMILAST) CREAM 0.15% AND 0.05% IMPROVED QUALITY OF LIFE, SPECIFICALLY BY HELPING TO REDUCE SLEEP DISRUPTIONS, AND PROVIDED LONG-TERM, DURABLE DISEASE CONTROL FOR INDIVIDUALS WITH ATOPIC DERMATITIS AGED 2 YEARS AND OLDER WILL BE PRESENTED AT THE 2025 FALL CLINICAL DERMATOLOGY CONFERENCE, TAKING PLACE OCTOBER 2326, 2025, IN LAS VEGAS.

ARCUTIS TO PRESENT NEW QUALITY OF LIFE AND LONG-TERM DATA WITH ZORYVE (ROFLUMILAST) CREAM 0.15% AND 0.05% FOR THE TREATMENT OF ATOPIC DERMATITIS AT THE FALL CLINICAL DERMATOLOGY CONFERENCE

ZORYVE CREAM 0.05% PROVIDES RAPID AND EFFECTIVE RELIEF OF MILD TO MODERATE ATOPIC DERMATITIS IN CHILDREN AGES 2 TO 5 AND IS SAFE AND WELL TOLERATED ONCE-DAILY, STEROID-FREE CREAM CAN BE USED ANYWHERE ON THE BODY FOR ANY DURATION ABOUT 1.8 MILLION CHILDREN AGES 2 TO 5 WITH ATOPIC DERMATITIS ARE TOPICALLY TREATED IN THE U.S. SIXTH FDA APPROVAL FOR ZORYVE IN JUST OVER THREE YEARS COMMERCIAL PRODUCT EXPECTED TO BE AVAILABLE BY THE END OF OCTOBER 2025 WESTLAKE VILLAGE, CALIF., OCT. 06, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR ZORYVE (ROFLUMILAST) CREAM 0.05% FOR THE TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN CHILDREN 2 TO 5 YEARS OF AGE.

FDA APPROVES ARCUTIS' ZORYVE (ROFLUMILAST) CREAM 0.05% FOR THE TREATMENT OF ATOPIC DERMATITIS IN CHILDREN AGES 2 TO 5

WESTLAKE VILLAGE, CALIF., OCT. 03, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 94,500 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK TO 12 NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF OCTOBER 1, 2025, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

WESTLAKE VILLAGE, CALIF., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT IT WILL REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON TUESDAY, OCTOBER 28, 2025, BEFORE THE U.S. FINANCIAL MARKETS OPEN.

Arcutis Biotherapeutics, Inc.

ARQT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Arcutis Biotherapeutics, Inc.

ARQT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ARQT